Plavix and PPIs
Executive Summary
Medco is adding evidence that proton pump inhibitors may reduce the effectiveness of Plavix (clopidogrel) and thus increase the risk of major cardiovascular events, based on a recent retrospective claims analysis. The analysis focused on medical/pharmacy claims for 16,690 patients who had undergone PCI and were started on Plavix, 9,862 who were taking the antiplatelet drug alone and 6,828 taking clopidogrel and a PPI. Over 12 months, the relative risk of a major adverse cardiovascular event was 50 percent higher and the relative risk of a heart attack specifically was 74 percent in patients taking both drugs. Medco has provided the results to FDA, which is reviewing the study, and is issuing its own alert. Aetna recently announced a retrospective claims analysis with similar findings (1"The Pink Sheet," Oct. 6, 2008, p. 8)
You may also be interested in...
Aetna Plans “Clinical Alert” On Plavix Use With PPIs Based On Claims Review
Aetna is developing a clinical alert for physicians and pharmacists to warn about potentially reduced effectiveness for Plavix (clopidogrel) when the antiplatelet drug is used concurrently with a proton pump inhibitor, such as Prilosec (omeprazole) or Nexium (esomeprazole)
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.